Status:

TERMINATED

Exercise Therapy for Asthma (ETA Trial)

Lead Sponsor:

Ohio State University

Conditions:

Asthma

Eligibility:

All Genders

18-50 years

Brief Summary

The purpose of the study is to determine if a program of regular exercise can help reduce asthma symptoms and also reduce the inflammation caused by asthma. If successful, this would allow regular exe...

Detailed Description

This is a randomized, controlled, parallel-design study of the effectiveness of exercise therapy as add-on therapy in the treatment of mild to moderately severe asthma. 105 men and women between the ...

Eligibility Criteria

Inclusion

  • • 18-50 years old
  • 50 + years old with prior approval to begin an exercise program from primary care physician within 6 months of enrollment
  • Men and women
  • Asthma:
  • Doctor diagnosed asthma
  • Lung function tests must meet certain levels common in asthma patients
  • Active, daily doctor-prescribed asthma controller medication (inhaled corticosteroid) for 2 months or longer at a minimum dose equivalent to fluticasone 88 mcg/day, about two (2) puffs. (you can be on other drugs as long as they are in the same dose range as fluticasone)
  • Poor asthma control: Any one of the following conditions:
  • Use of beta-agonist (A bronchodilator medicine that opens the airways by relaxing the muscles around the airways that may tighten during an asthma attack )for asthma symptoms twice/week or more OR
  • Awakening from sleep with asthma symptoms more than once per week OR
  • One or more control problems identified on the Asthma Treatment and Control Questionnaire (ATAQ).
  • Smoking status:
  • Non-smoker for 6 months or longer
  • Less than 10 pack year (number of packs per day (x) years of smoking = pack years) smoking history

Exclusion

  • • Poor lung function
  • Current participation in a regular aerobic exercise program (formal or at home)
  • Any "yes" to any one of items a-e of question number two of the Stanford Usual Activity Questionnaire
  • Pregnancy
  • Sudden illness that accompanies fever (\> 38.00 C or 100.40F) within 24 hours of Visit 2
  • Participation in another interventional research trial Other major chronic illnesses that would interfere with participation in the study
  • Medication use:
  • Chronic oral corticosteroid use
  • Oral corticosteroid use within 4 weeks of study start
  • Anti-coagulants (An anticoagulant is a drug that helps prevent the clotting (coagulation) of blood.), insulin, any investigative drugs within 2 months
  • Drug allergy:
  • • Previous adverse effects from methacholine challenge
  • Non-adherence:
  • Inability or unwillingness to provide consent
  • Inability to perform aerobic exercise
  • Inability to perform baseline measurements
  • Less than 80% completion of screening period diaries
  • Inability to contact by telephone
  • Intention to move out of the area within 6 months

Key Trial Info

Start Date :

December 1 2003

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2009

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00839137

Start Date

December 1 2003

End Date

December 1 2009

Last Update

November 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Ohio State University

Columbus, Ohio, United States, 43210